Examining voice and speech changes during manic episodes
Computational Analysis of Spoken Language in Mania
This study looks at how voice and speech change during manic episodes in people with Bipolar I Disorder to help improve future treatments.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT05956340 on ClinicalTrials.gov |
What this trial studies
This study investigates the alterations in voice and speech patterns that occur during episodes of mania in individuals diagnosed with Bipolar I Disorder. Participants will undergo research interviews to assess these changes while they are hospitalized or in the Emergency Department. The goal is to better understand the relationship between manic episodes and communication characteristics, which may inform future treatment approaches.
Who should consider this trial
Good fit: Ideal candidates are English-speaking individuals with a documented clinical diagnosis of Bipolar I Disorder who are currently hospitalized for mania.
Not a fit: Patients who are currently involuntarily hospitalized or have a positive urine drug screen for certain substances may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic tools and treatment strategies for individuals experiencing mania.
How similar studies have performed: While this specific approach is novel, similar studies examining speech and language in psychiatric conditions have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Provision of informed consent before any study procedures are performed * English speaker * Documented clinical diagnosis for Bipolar I Disorder * Undergoing hospitalization, or boarding in the Emergency Department, for mania as determined by primary clinical staff Exclusion Criteria: * Positive urine drug screen for amphetamines or cocaine. * Expressing paranoid delusions regarding electronic surveillance. * Documented clinical diagnosis of developmental delay. * Currently involuntarily hospitalized. * Deemed at risk for aggression. * Failure to comprehend study objectives via comprehension questionnaire. * Individuals who have a guardian and are unable to consent for themselves. * Current communicable disease requiring isolation.
Where this trial is running
Rochester, Minnesota
- Mayo Clinic Minnesota — Rochester, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Mark Frye, MD — Mayo Clinic
- Study coordinator: Jeremiah Joyce, MD, MS
- Email: Joyce.Jeremiah@mayo.edu
- Phone: 507-284-0557
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.